Nasopharyngeal-Type Undifferentiated Carcinoma
NCI Definition: A nonkeratinizing carcinoma which occurs predominantly in the nasopharynx but also in the tonsils and rarely in other anatomic sites. It is characterized by the presence of large malignant cells with vesicular nuclei, prominent nucleoli, syncytial growth pattern, and a lymphoplasmacytic infiltrate. 
Nasopharyngeal-type undifferentiated carcinomas most frequently harbor alterations in TP53, TGFBR2, SETD2, PPM1D, and PIK3CA .
TP53 c.217-c.1178 Missense, TP53 R158L, TP53 Mutation, TP53 Missense, and TP53 Exon 5 Mutation are the most common alterations in nasopharyngeal-type undifferentiated carcinoma .
There is 1 clinical trial for nasopharyngeal-type undifferentiated carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains nasopharyngeal-type undifferentiated carcinoma as an inclusion criterion, 1 is phase 3 (1 open).
Gemcitabine and nivolumab are the most common interventions in nasopharyngeal-type undifferentiated carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.